CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 491 enrolled
Drug / intervention
Paliperidonedrug
Likely dose
Paliperidone 12 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00761189
NCT00761189Phase 4Completed
CompareCT.gov

An Open Label, Prospective, Non-comparative Study to Evaluate Flexible Dose of Paliperidone Extended-Release and Clinical Response in the Treatment of Subjects With Schizophrenia

Janssen Korea, Ltd., Korea·interventional·Posted Sep 29, 2008·Updated Mar 5, 2014

In Brief

A Phase 4 clinical trial evaluating Paliperidone for Schizophrenia. Completed, enrolled 491 participants across 20 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy of paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 29, 2008
Enrollment StartFeb 1, 2008
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17.8 years ago

Interventions

Paliperidonedrug

Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.